Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): A review of evidences and recommendations

Vaccine

Volumn 30, Issue 35, 2012, Pages 5179-5190

  Bechini, Angela ^a   Tiscione, Emilia ^a   Boccalini, Sara ^a   Levi, Miriam ^a   Bonanni, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acellular pertussis vaccination; Adolescents; Pertussis prevention; Pregnant women; Risk groups

Indexed keywords

PERTUSSIS VACCINE;

ADOLESCENT; CELLULAR IMMUNITY; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MORBIDITY; NEWBORN; PERTUSSIS; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADOLESCENT; ADULT; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HEALTH PERSONNEL; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT, NEWBORN; PREGNANCY; TOXOIDS; VACCINATION; WHOOPING COUGH;

EID: 84863813830     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.005     Document Type: Review

References (135)

1. Kretsinger K., Broder K.R., Cortese M.M. Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by Healthcare Infection Control Practices Advisory Committee (HICPCAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006, 55(RR-17):1-37.
2. Wendelboe A.M., Van Rie A., Salmaso S., Englund A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
3. Singh M., Lingappan K. Whooping Cough. Chest 2006, 130:1547-1553.
4. Zhang L., Prietsch S.O.M., Axelsson I., Halperin S.A. A cellular vaccines for preventing whooping cough in children. Cochrane Database of Syst Rev 2008, (2). Art. No.: CD001478. 10.1002/14651858.CD001478.pub3.
5. WHO Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010, 85(40):385-400.
6. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984, 1(8369):122-126.
7. European Centre for Disease Prevention and Control. ECDC Guidance. Scientific panel on childhood immunisation schedule: Diphtheria-tetanus-pertussis (DTP) vaccination. Stockholm: ECDC; 2009.
8. Cherry J.D. The present and future control of pertussis. Clin Infect Dis 2010, 51(6):663-667.
9. Kuno-Sakai H., Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int. 2004, 46(6):650-655.
10. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC; 2011.
11. Kirchner J.T. Tdap vaccine: current indications for adolescent and adult patients in the United States. J Am Osteopath Assoc 2011, 111(10 Suppl. 6):S7-S9.
12. Halperin B.A., Halperin S.A. The reemergence of pertussis and infant deaths: is it time to immunize pregnant women?. Future Microbiol 2011, 6(4):367-369.
13. Galanis E., King A.S., Varughese P., Halperin S.A. On behalf of the IMPACT investigators: changing epidemiology and emerging risk groups for pertussis. CMAJ 2006, 174(4):451-452.
14. Skowronski D.M., De Serres G., MacDonald D., et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002, 185(10):1448-1453.
15. Güriş D., Strebel P.M., Bardenheier B., et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999, 28(6):1230-1237.
16. Tan T., Trindade E., Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005, 24(Suppl. 5):S10-S18.
17. Broder K.R., Cortese M.M., Iskander J.K., Kretsinger K., Slade B.A., Brown K.H., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-3):1-34.
18. Wirsing von Konig C.H., Riffelman M. Pertussis: an old disease in new clothes. Euro Surveill 2007, 12(9):E1-E2. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=727.
19. Centers for Disease Control Prevention (CDC) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60(41):1424-1426.
20. Ulloa-Gutierrez R., Boza R., Carvajal-Riggioni D., Baltodano A. Pertussis: should we improve intensive care management or vaccination strategies?. Expert Rev Vaccines 2011, 10(1):49-53.
21. Olin P., Gustafsson L., Barreto L., et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003, 21:2015-2021.
22. Salmaso S., Mastrantonio P., Tozzi A.E., et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001, 108:E81.
23. Juretzko P., von Kries R., Hermann M., Wirsing von König C.H., Weil J., Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002, 35(2):162-167.
24. Rendi-Wagner P., Kundi M., Mikolasek A., Vécsei A., Frühwirth M., Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 2006, 24(33-34):5960-5965.
25. Kuno-Sakai H., Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int 2004, 46(6):650-655.
26. American Academy of Pediatrics Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 2006, 117:965-978.
27. Crowcroft N.S., Pebody R.G. Recent developments in pertussis. Lancet 2006, 367(9526):1926-1936.
28. Wilson T.R. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. J Pediatr Health Care 2006, 20(4):229-237.
29. Celentano L.P., Massari M., Paramatti D., Salmaso S., Tozzi A.E. EUVAC-NET group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005, 24(9):761-765.
30. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., Jha P., Campbell H., Walker C.F., Cibulskis R., Eisele T., Liu L., Mathers C. Child health epidemiology reference group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375(9730):1969-1987.
31. EUVAC.NET. Pertussis Surveillance Report 2003-2007. Available at: http://www.ecdc.europa.eu/en/publications/Publications/pertussis_report_2003_2007_euvacnet.pdf.
32. Guiso N., Wirsing von Konig C.H., Forsyth K., Tan T., Plotkin S.A. The Global Pertussis Initiative: Report from a Round Table Meeting to discuss the Epidemiology and Detection of Pertussis. Vaccine 2011, 29(6):1115-1121. Epub 2010 Dec 17.
33. Judelsohn R.G., Koslap-Petraco M.B. Public health perspectives on the rising incidence of pertussis. Public Health Nurs 2007, 24(5):421-428.
34. Heininger U., Cherry J.D. Pertussis immunisation in adolescents and adults-Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther 2006, 6(7):685-697.
35. Franco E., Giambi C., Ialacci R., Maurici M. Pertussis vaccination for adolescents and adults. Expert Opin Biol Ther 2004, 4(10):1669-1676.
36. Mooi F.R., van Loo I.H.M., van Gent M., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15(8):1206-1213.
37. Mooi F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 2010, 10:36-49.
38. Faulkner A., Skoff T., Martin S., Cassiday P., Tondella M.L., Liang J., Ejigiri G. Chapter 10 Pertussis. VPD surveillance manual 2011, Available at: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt10-pertussis.html, 5th ed.
39. Centers for Disease Control and Prevention (CDC). Best practices for health care professionals on the use of Polymerase Chain Reaction (PCR) for Diagnosing Pertussis. Available at: [accessed December 5, 2011]. http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html.
40. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., Rebmann C.A., Gabel J., Schauer S.L., Lett S.M. Infant pertussis: who was the source?. Pediatr Infect Dis J 2004, 23:985-989.
41. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D.D., Gaudelus J., Gerber M., Grimprel E., Greenberg D., Halperin S., Liese J., Munoz-Rivas F., Teyssou R., Guiso N., Van Rie A. For the infant Pertussis study group. Transmission of Bordetella pertussis to Young infants. Pediatr Infect Dis J 2007, 26(4):293-299.
42. Kowalzik F., Barbosa A.P., Fernandes V.R., et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007, 26:238-242.
43. Gerbie M.V., Tan T.Q. Pertussis disease in new mothers: effect on young infants and strategies for prevention. Obstet Gynecol 2009, 113(2 Pt 1):399-401.
44. Cortese M.M., Baughman A.L., Brown K., Srivastava P. A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 2007, 32(3):177-185.
45. Gehanno J.F., Pestel-Caron M., Nouvellon M., Caillard J.F. Nosocomial pertussis in healthcare workers from a pediatric emergency unit in France. Infect Control Hosp Epidemiol 1999, 20(8):549-552.
46. Steketee R.W., Wassilak S.G.F., Adkins W.N., Burstyn D.G., Manclark C.R., Berg J., et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis 1988, 157:434-440.
47. Addiss D.G., Davis J.P., Meade B.D., Burstyn D.G., Meissner M., Zastrow J.A., et al. A pertussis outbreak in a Wisconsin nursing home. J Infect Dis 1991, 164:704-710.
48. Kurt T.L., Yeager A.S., Guenette S., Dunlop S. Spread of pertussis by hospital staff. JAMA 1972, 221:264-267.
49. Crameri S., Heininger U. Successful control of a pertussis outbreak in a university children's hospital. Int J Infect Dis 2008, 12(6):e85-e87.
50. Pascual F.B., McCall C.L., McMurtray A., Payton T., Smith F., Bisgard K.M. Outbreak of pertussis among healthcare workers in a hospital surgical unit. Infect Control Hosp Epidemiol 2006, 27(6):546-552.
51. Bryant K.A., Humbaugh K., Brothers K., Wright J., Pascual F.B., Moran J., Murphy T.V. Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker. Infect Control Hosp Epidemiol 2006, 27(6):541-545.
52. WHO Vaccine Preventable Diseases Monitoring System [Internet]. Geneva: World Health Organization; 2011. Available from: [accessed 14 May 2012]. http://apps.who.int/immunization_monitoring/en/globalsummary/DiseaseSelect.cfm%3FU=years.
53. Gall S.A. Vaccines for pertussis and influenza: recommendations for use in pregnancy. Clin Obstet Gynecol 2008, 51(3):486-497.
54. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47:401-409.
55. Gabutti G., Bergamini M., Bonanni P., Guido M., Fenoglio D., Giammanco A., Sindoni L., Zotti C., Boddi V., Bamfi F., Severini R., Bechini A., Boccalini S., Crovari P. Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy. Epidemiol Infect 2008, 136:1576-1584. Collaborative Group for the Study of Pertussis.
56. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
57. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16:1901-1906.
58. Olin P., Hallander H.O., Gustafsson L., Reizenstein E., Storsaeter J. How to make sense of pertussis immunogenicity data. Clin Infect Dis 2001, 33:S288-S291.
59. Pichichero M.E., Casey J.R. Acellular pertussis vaccines for adolescents. Pediatr Infect Dis J 2005, 24(Suppl. 6):S117-S126.
60. Cherry J.D. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997, 16(Suppl. 4):S90-S96.
61. Munoz F.M. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Semin Pediatr Infect Dis 2006, 17:14-19.
62. Casey J.R., Pichichero M.E. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 2005, 65(10):1367-1389.
63. Food and Drug Administration. Product approval information-licensing action, package insert: BOOSTRIX®. Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed. GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005.
64. Food and Drug Administration. Product approval information-licensing action, package insert: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed ADACEL™. Sanofi pasteur. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.
65. Tran Minh N.N., He Q., Ramalho A., Kaufhold A., Viljanen M.K., Arvilommi H., Mertsola J. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999, 104:e70-e76.
66. Edelman K., He Q., Mäkinen J., Sahlberg A., Haanperä M., Schuerman L., Wolter J., Mertsola J. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44(10):1271-1277.
67. Pichichero M.E., Rennels M.B., Edwards K.M., Blatter M.M., Marshall G.S., Bologa M., et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005, 293:3003-3011.
68. Pichichero M.E., Blatter M.M., Kennedy W.A., Hedrick J., Descamps D., Friedland L.R. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006, 117(4):1084-1093.
69. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Keitel W., Edwards K., Lee M., Treanor J., Greenberg D.P., Barenkamp S., Bernstein D.I., Edelman R. APERT study group. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized acellular pertussis vaccine trial (APERT). Clin Infect Dis 2006, 43:151-157.
70. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Lee H., Treanor J., Greenberg D.P., Keitel W., Barenkamp S., Bernstein D.I., Edelman R., Edwards K. APERT study group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353:1555-1563.
71. Sin M.A., Zenke R., Rönckendorf R., Littmann M., Jorgensen P., Hellenbrand W. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Pediatr Infect Dis J 2009, 28(3):242-244.
72. Rendi-Wagner P., Paulke-Korinek M., Stanek G., Khanakah G., Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007, 26(9):806-810.
73. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a north american outbreak. Clin Infect Dis 2012, 54(12):1730-1735.
74. National Health Medical Research Council The Australian immunization handbook 2003, Australian Government Department of Health and Ageing, Canberra.
75. Rank C., Quinn H.E., McIntyre P.B. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009, 28(2):152-153.
76. Quinn H.E., McIntyre P.B. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ 2011, 89(9):666-674.
77. Wei S.C., Tatti K., Cushing K., Rosen J., Brown K., Cassiday P., Clark T., Olans R., Pawloski L., Martin M., Tondella M.L., Martin S.W. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010, 51(3):315-321.
78. Skoff T.H., Cohn A.C., Clark T.A., Messonnier N.E., Martin S.W. Early impact of the US Tdap vaccination program on pertussis trends. Arch Pediatr Adolesc Med 2012, 166(4):344-349.
79. Francis P.T. Maternal vaccination against pertussis. Lancet Infect Dis 2008, 8(4):214. author reply 214-5.
80. Van Rie A., Wendelboe A.M., Englund J.A. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005, 24(Suppl. 5):S62-S65.
81. Sauerbrei A., Prager J., Bischoff A., Wutzler P. Antibodies against vaccine-preventable diseases in pregnant women and their offspring. Diphtheria, pertussis, tetanus. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004, 47(1):16-20.
82. Di Sant'Agnese P. Simultaneous immunization of newborn infants against diphtheria, tetanus, and pertussis. Am J Public Health 1950, 40:674-680.
83. Provenzano R., Wetterlow L., Sullivan C. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of life. N Eng J Med 1965, 273:959-965.
84. Adams J., Kimball A., Adams F. Early immunization against pertussis. Am J Dis Child 1947, 74:10-18.
85. Miller J., Faber H., Ryan M., Silverberg R., Lew E. Immunization against pertussis during the first four months of life. Pediatrics 1949, 4:468-478.
86. Healy C.M., Munoz F.M., Rench M.A., Halasa N.B., Edwards K.M., Baker C.J. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004, 190(2):335-340.
87. Gall S.A., Myers J., Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011, 204:334.e1-334.e5.
88. Leuridan E., Hens N., Peeters N., de Witte L., Van der Meeren O., Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011, 30(7):608-610.
89. Van Savage J., Decker M.D., Edwards K.M., Sell S.H., Karzon D.T. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990, 161:487-492.
90. Englund J.A., Anderson E.L., Reed G.F., et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995, 96(3 Pt 2):580-584.
91. Hardy-Fairbanks A.J., Pan S.J., Johnson D.R., Bernstein H.H. Immune responses in infants following receipt of pertussis immunization by their mothers during pregnancy. Presented at the 48th Infectious Diseases Society of America Annual Meeting 2010.
92. Dalhousie University. Pertussis maternal immunization study. Identifier: NCT00553228. Available at: [accessed December 5, 2011]. http://clinicaltrials.gov/show/nct00553228.
93. National Institute of Allergy and Infectious Diseases. Pertussis vaccine in healthy pregnant women. Identifier: NCT00707148. Available at: [accessed December 5, 2011]. http://clinicaltrials.gov/show/nct00707148.
94. Castagnini L.A., Healy C.M., Rench M.A., Wootton S.H., Munoz F.M., Baker C.J. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis 2012, 54(1):78-84.
95. Healy C.M., Rench M.A., Castagnini L.A., Baker C.J. Pertussis immunization in a high-risk postpartum population. Vaccine 2009, 27:5599-5602.
96. Healy C.M., Rench M.A., Baker C.J. Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis 2011, 52:157-162.
97. Dylag A.M., Shah S.I. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Pediatrics 2008, 122(3):e550-e555.
98. Siegrist C.A. Vaccination in the neonatal period and early infancy. Int Rev Immunol 2000, 19(2-3):195-219.
99. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 2001, 19:3331-3346.
100. Halasa N.B., O'Shea A., Shi J.R., LaFleur B.J., Edwards K.M. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008, 153(3):327-332.
101. Knuf M., Schmitt H.J., Wolter J., Schuerman L., Jacquet J.M., Kieninger D., Siegrist C.A., Zepp F. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008, 152(5):655-660.
102. Knuf M., Schmitt H.J., Jacquet J.M., Collard A., Kieninger D., Meyer C.U., Siegrist C.A., Zepp F. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr 2010, 156(4):675-678.
103. Wood N., McIntyre P., Marshall H., Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010, 29(3):209-215.
104. Riffelmann M., Littmann M., Hülsse C., von König C.H. Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine. Eur J Clin Microbiol Infect Dis 2009, 28(3):275-279.
105. Littmann M., Hülsse C., Riffelmann M., Wirsing von König C.H. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers. Vaccine 2008, 26(19):2344-2349.
106. Christie C.D.C., Garisson K.M., Kiely L., Gupta R.K., Heubi J., Marchant C.D. A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993. Clin Infect Dis 2001, 33:997-1003.
107. Hees L., Afroukh N., Floret D. Vaccination coverage among health care workers in the pediatric emergency and intensive care department of Edouard Herriot hospital in 2007, against influenza, pertussis, varicella, and measles. Arch Pediatr 2009, 16(1):14-22.
108. Centers for Disease Control Prevention (CDC) Updated recommendations for the use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011, 60(1):13-15.
109. Centers for Disease Control and Prevention (CDC) Recommended adult immunization schedule-United States, 2011. MMWR Morb Mortal Wkly Rep 2011, 60(4):1-4.
110. Pickering L.K., Baker C.J., Freed G.L., Gall S.A., Grogg S.E., Poland G.A., Rodewald L.E., Schaffner W., Stinchfield P., Tan L., Zimmerman R.K., Orenstein W.A. Infectious Diseases Society of America. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49(6):817-840.
111. Centers for Disease Control and Prevention (CDC) FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR 2009, 58(14):374-375.
112. Centers for Disease Control and Prevention (CDC) FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR 2011, 60:1279-1280.
113. Forsyth K.D., Wirsing von Konig C.H., Tan T., Caro J., Plotkin S. Prevention of pertussis: recommendations derived from the second global pertussis initiative roundtable meeting. Vaccine 2007, 25(14):2634-2642.
114. National Advisory Committee on Immunization (NACI) Statement on the prevention of pertussis in adolescents and adults. Can Commun Dis Rep 2003, 29(ACS-5):1-9. Available at: http://www.collectionscanada.gc.ca/webarchives/20071125012112/http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/03pdf/acs-dcc-29-5-6.pdf.
115. Regione Toscana. Aggiornamento direttive regionali in materia di vaccinazioni. Deliberazione n. 1020 del 27/12/2007. Revoca delibere n. 1249 del 24/11/2003, n.379 del 7/3/2005 e n.1060 del 10/10/2000. Modifica delibera n. 1386 del 17/12/2001. Bollettino Ufficiale Regione Toscana n°2 del 9 gennaio 2008. Available at: http://web.rete.toscana.it/attinew.
116. Regione Puglia. Deliberazione Giunta regionale n. 2068 del 28/09/2010. Commissione tecnico-scientifica regionale vaccini - Modifica del Calendario Vaccinale della Regione Puglia per l'anno 2009 approvato con D.G.R. n.1286/09. Adozione del Calendario Vaccinale della Regione Puglia per l'anno 2010. Bollettino Ufficiale della Regione n.159 del 19 ottobre 2010. Available at: http://www.regione.puglia.it/index.php%3Fpage=curp%26opz=display%26id=5398.
117. European Centre for Disease Prevention and Control (ECDC). Pertussis vaccination overview in European countries. Available at: http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules/Pages/pertussis_schedule.asp.
118. Centers for Disease Control and Prevention (CDC). Updated Tdap vaccination coverage rates. 2009 Adult vaccination coverage, National Interview Survey. Available at [accessed December 5, 2011]. http://www.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm.
119. Istituto Superiore di Sanità. ICONA 2008: national vaccination coverage survey among children and adolescents. ICONA Working Group. 2009, viii, 118 p. Rapporti ISTISAN 09/29 [in Italian].
120. Centers for Disease Control and Prevention (CDC) Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep 2008, 57(40):1100-1103.
121. Centers for Disease Control and Prevention (CDC) National and state vaccination coverage among adolescents aged 13-17 years-United States, 2010. MMWR 2011, 60:1117-1123.
122. Wilson TR. Author's response. J Pediatr Health Care 2006; 20:430; author reply 430. Refers to: Lovette B. Update on adolescent immunization. J Pediatr Health Care 2006; 20(6):430.
123. Middleman A.B., Bruner A. Tetanus, diphtheria, and acellular pertussis vaccine: a position statement of the Society for Adolescent Medicine. J Adolesc Health 2009, 45(3):316-317.
124. Murphy T.V., Slade B.A., Broder K.R., Kretsinger K., Tiwari T., Joyce P.M., Iskander J.K., Brown K., Moran J.S. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-4):1-51.
125. Mooi F.R., de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007, 7(9):614-624.
126. Baraff L.J., Leake R.D., Burstyn D.G., et al. Immunologic response to early and routine DTP immunization in infants. Pediatrics 1984, 73(1):37-42.
127. Goldschneider I., Lepow M.L., Gotschlich E.C., Mauck F.T., Bachl F., Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis 1973, 128(6):769-776.
128. Gold R., Lepow M.L., Goldschneider I., Gotschlich E.C. Immune response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 1977, 136(Suppl.):S31-S35.
129. Kurikka S., Kayhty H., Peltola H., Saarinen L., Eskola J., Makela P.H. Neonatal immunization: response to Haemophilus influenza type b- tetanus toxoid conjugate vaccine. Pediatrics 1995, 95(6):815-822.
130. Lieberman J.M., Greenberg D.P., Wong V.K., et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995, 126(2):198-205.
131. Leach A., Twumasi P.A., Kumah S., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide- protein conjugate vaccine. J Infect Dis 1997, 175(1):200-204.
132. Wendelboe A.M., Hudgens M.G., Poole C., Van Rie A. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol 2007, 4:15.
133. Zimmerman R.K., Middleton D.B. Vaccines for persons at high risk, 2007. J Fam Pract 2007, 56(2 Suppl. Vaccines):S38-S46. C4-5.
134. Centers for Disease Control and Prevention (CDC) Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices [ACIP] and the Hospital Infection Control Practices Advisory Committee [HICPAC]. MMWR Recomm Rep 1997, 46(RR-18):1-42.
135. Centers for Disease Control and Prevention (CDC) Immunization of health-care personnel. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011, 60(7):1-46.